Ritonavir Conference Data

Medical Advocates
Ritonavir (Norvir)

Conference Citations

6th IAS Conference
18th CROI
XVIII International AIDS Conference
Ninth Int Congress on Drug Therapy in HIV Infection
XVII International AIDS Conference
15th CROI
11th European AIDS Conference
XVI International AIDS Conference
13th CROI
11th CROI
41st ICAAC

ARV Drugs Main Page Ritonavir Main Page Home Page

Last Update: July 27, 2011
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

6th IAS Conference

POSTER
Intracellular accumulation of ritonavir in boosted protease inhibitors regimens and correlations between plasma
and PBMC concentrations
A. D'Avolio, M. Simiele, M. Siccardi, et al
Poster     Abtsract

18th Conference on Retroviruses and Opportunistic
Infections

POSTER
Low-dose RTV and the Pharmacokinetics of the Investigational HCV Protease Inhibitor TVR in Healthy Volunteers
V Gar, X Luo, L McNair, et al
PDF Poster     Abstract

XVIII International AIDS Conference

POSTER
Late treatment failures in CSF in patients on long-term maintenance ART with ritonavir-boosted
PI monotherapy.
C. Kahlert, A. Witteck, C. Gutmann, et al
PDF Poster     Abstract

Ninth Int Congress on Drug Therapy in HIV Infection

POSTER
The Effect of Food on Ritonavir Bioavailability Following Administration of Ritonavir 100 mg Film-Coated
Tablet in Healthy Adult Subjects
CE Klein, YL Chiu, W Awni, et al
PDF Poster

XVII International AIDS Conference

POSTER
Effects of nucleoside analogues versus ritonavir boosted protease inhibitors on lipid levels � analysis of 12 clinical
trials in 4231 antiretroviral na�ve patients
A Hill, B Gazzard
PowerPoint Poster
A WEEK IN REVIEW FEATURED REPORT
POSTER
A Comparison of the Single Dose Bioavailability of a Ritonavir Tablet Formulation Relative to the Ritonavir
Soft Gelatin Capsule in Healthy Adult Subjects
J Ng, CE Klein, SJ Causemaker, et al
PDF Poster

15th Conference on Retroviruses and Opportunistic
Infections

Plasma Exposure of 100 mg Once and Twice Daily Decreases HDL and CD36
Expression but Only Twice-daily Dosing Increases Triglycerides: Potential Effect of
RTV on Cardiovascular Disease
M Boffito, S Collot-Teixeira, F De Lorenzo, et al
Abstract

11th European AIDS Conference

POSTER
Ritonavir Pharmacokinetics in Subjects 60 Years or Older
CE Klein, Y-L Chiu, J Li, et al
11th European AIDS Conference
PDF Poster

XVI International AIDS Conference

Long-term safety and effectiveness of ritonavir (RTV), nelfinavir (NFV) and lopinavir/ritonavir (LPV/r)
in antiretroviral (ARV) -experienced HIV-1-infected children
Rudin C., Burri M., Shen Y., et al
Abstract

13th Conference on Retroviruses and Opportunistic
Infections

High Risk of Unrecognized Adrenal Suppression and Symptoms of Steroid Excess in HIV⁺
Clinic Patients Exposed to Ritonavir and Topical Fluticasone: Results of a Case-control Study
M Hull, E Phillips, M Harris, et al
Abstract
The Predictive Value of Pharmacokinetic-adjusted Phenotypic Susceptibility on
Antiretroviral Response to Ritonavir-enhanced Protease Inhibitors in Subjects Who
Failed Previous PI-based Regimens: ACTG A5126
JJ Eron, G Park, R Haubrich, et al
Abstract
Ritonavir Nanoparticles Inhibit Productive Replication of HIV-1ADA in MDM
A Ghorpade, K Rao, P Sahoo, et al
Abstract
POSTER
Evaluation of Ritonavir/Saquinavir-based Regimens in the Prevention of MTCT of HIV
M Hanlon, S O'Dea, H McDermott, et al
PDF Poster     Abstract

11th Conference on Retroviruses and Opportunistic
Infections

(Note: Data on the use of ritonavir to boost efficacy of other ARVs are indexed under the primary ARV)

POSTER
Evolution of Genotypic Resistance and Pharmacokinetic Measures of Adherence in
Children Failing Ritonavir/Indinavir Combination Regimens
EG Chadwick, JH Rodman, P M Samson, et al
PDF Poster            Abstract

ARV Drugs Main Page Ritonavir Main Page Home Page

RITONAVIR
Conference Reports, Abstracts, and Posters